A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia.

Trial Profile

A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Moxetumomab pasudotox (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions; Pharmacogenomic; Registrational; Therapeutic Use
  • Most Recent Events

    • 01 Apr 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 01 Apr 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 24 Sep 2012 Planned End Date changed from 1 Feb 2015 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top